What was changed
In August 2020, while hospitals were still absorbing the pandemic shock, Siemens Healthineers agreed to buy Varian Medical Systems for $177.50 a share, or about $16.4 billion. The decision moved the German imaging and diagnostics group from tools around care into a fuller cancer-care platform.
The acquisition was not framed as a bargain-hunting bolt-on. Siemens Healthineers said Varian would strengthen its position in healthcare, be accretive to adjusted EPS within 12 months after closing, and produce at least EUR300 million of annual EBIT synergies in fiscal 2025.
When the deal closed in April 2021, Varian became a new business segment. Siemens Healthineers said the combined company would integrate imaging, lab diagnostics, AI and treatment across oncology, turning the 2020 crisis into an upgrade of its operating architecture.
What it achieved
The deal created a new Varian segment and targeted at least EUR300M of annual EBIT synergies by fiscal 2025.
Why it worked
Varian filled the treatment layer that Siemens Healthineers lacked in cancer care.
The company made the deal large enough to change its segment structure, not just add products.
Management attached concrete synergy and EPS targets, which made the crisis acquisition measurable.
What can be applied
A crisis can be the moment to buy the missing layer of a platform, if the balance sheet and integration logic are ready.
Aftermath
Varian became a separate Siemens Healthineers segment after closing. The combined company positioned itself as a partner across the cancer-care continuum, with Strategy 2025 built around a broader, more integrated health-technology portfolio.
FOLLOW THE EVIDENCE